Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities

Kate Roberts1, Vanessa Culleton1, Zarnie Lwin1,2,3

  • 1Cancer Care Services, The Prince Charles Hospital, Brisbane, Queensland, Australia.

Insights

Immune checkpoint inhibitors offer new cancer treatments but can cause unique immune-related side effects. This review details these toxicities and provides management guidelines for better patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Immune checkpoint inhibitors represent a significant advancement in cancer therapy.
  • These novel agents are associated with a distinct spectrum of immune-related adverse events.
  • Effective management of these toxicities is crucial for patient safety and treatment success.

Purpose of the Study:

  • To comprehensively review immune-related toxicities associated with immune checkpoint inhibitors.
  • To provide evidence-based recommendations for the investigation of these adverse events.
  • To outline guidelines for the specific management of immune-based toxicities.

Main Methods:

  • Literature review of immune checkpoint inhibitor-related toxicities.
  • Synthesis of current clinical guidelines and expert opinions.
  • Analysis of reported adverse event profiles and management strategies.

Main Results:

  • Detailed description of common and rare immune-related toxicities.
  • Categorization of toxicities by organ system affected.
  • Summary of diagnostic approaches and therapeutic interventions.

Conclusions:

  • Early identification and prompt management of immune-related toxicities are essential.
  • Adherence to established guidelines can optimize patient outcomes.
  • Understanding and addressing these unique toxicities are critical for the safe and effective use of immune checkpoint inhibitors.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
684
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
54
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
81